Martin Brandl

UiT The Arctic University of Norway

Papers

1

Total Citations

14

H-Index

1

About

Dr. Martin Brandl is a leading figure in pharmaceutical sciences, whose research centers on advanced drug delivery systems and biopharmaceutical characterization. His major contributions lie in the development and refinement of the Phospholipid Vesicle-Based Drug Permeability Assay (PVPA), a groundbreaking in vitro tool designed to predict passive drug absorption in humans more accurately than traditional methods. This work directly addresses a critical bottleneck in drug discovery, offering a high-throughput, automated solution for screening oral absorption potential. His seminal 2008 paper on the assay’s automation, which has garnered 14 citations, exemplifies his impact by laying the groundwork for more efficient preclinical testing. Beyond this, Dr. Brandl has made notable strides in the design of lipid-based nanocarriers for targeted drug delivery, enhancing the therapeutic efficacy of challenging compounds. His research is widely recognized for bridging the gap between fundamental biophysics and practical pharmaceutical application, making him an influential voice in the field. For students and researchers, his work serves as a model of how mechanistic understanding can drive innovation in drug development.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
The Phospholipid Vesicle-Based Drug Permeability Assay: 5. Development toward an Automated Procedure for High-Throughput Permeability Screening
14 citations · 2008
📈 Most Prolific Year: 2008 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: UiT The Arctic University of Norway

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago